Last Updated on August 26, 2021 by The Health Master
Following the Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year, Lupin Healthcare has launched Luforbec (beclometasone / formoterol) 100/6 dose pressurised metered dose inhaler (pMDI).
It is available now to patients in the UK, with the potential to offer significant cost savings for the NHS, the company said in a statement.
Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 <50 per cent predicted normal).
Lupin is approved to manufacture Luforbec at its sites in Pithampur in India and Coral Springs in the US, added the statement.